Figure 1
Figure 1. Ability of TCR-encoding plasmids to vaccinate against T-cell lymphoma. (A) Mice were immunized 5 times at weekly intervals by gene gun with pVax-plasmids encoding the α chain alone (not shown), β chain alone (●), or with a combination of both delivered on the same gold particles (♦) followed by tumor challenge with 105 subcutaneously implanted MBL-2 lymphoma cells (mean ± SEM of 6 mice/group). The finding was confirmed in 7 independent experiments. (B) To examine the impact of the route of delivery on tumor protection, TCR-β–plasmid (50 μg plasmid/immunization) was injected intradermally 5 times at weekly intervals followed by MBL-2 tumor challenge as in panel A (n = 10 mice/group). Representative data from 1 of 2 experiments are shown (mean ± SEM).

Ability of TCR-encoding plasmids to vaccinate against T-cell lymphoma. (A) Mice were immunized 5 times at weekly intervals by gene gun with pVax-plasmids encoding the α chain alone (not shown), β chain alone (●), or with a combination of both delivered on the same gold particles (♦) followed by tumor challenge with 105 subcutaneously implanted MBL-2 lymphoma cells (mean ± SEM of 6 mice/group). The finding was confirmed in 7 independent experiments. (B) To examine the impact of the route of delivery on tumor protection, TCR-β–plasmid (50 μg plasmid/immunization) was injected intradermally 5 times at weekly intervals followed by MBL-2 tumor challenge as in panel A (n = 10 mice/group). Representative data from 1 of 2 experiments are shown (mean ± SEM).

Close Modal

or Create an Account

Close Modal
Close Modal